The correlation between novel antidiabetic agents utilization and hepatocellular carcinoma incidence in type 2 diabetes patients: a network meta-analysis

Aug 11, 2025European journal of clinical pharmacology

Links between new diabetes drugs use and liver cancer rates in type 2 diabetes patients

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

A total of 18,212,739 participants were included in the analysis of antidiabetic agents and hepatocellular carcinoma incidence.

SGLT-2 inhibitors were found to be the most effective in reducing the incidence of hepatocellular carcinoma in patients with type 2 diabetes.
SGLT-2 inhibitors and glucagon-like peptide-1 receptor agonists were most effective for decreasing the incidence of hepatic cirrhosis.
SGLT-2 inhibitors, glucagon-like peptide-1 receptor agonists, and DPP-4 inhibitors showed varying effectiveness in reducing hepatic metabolic dysfunction.
Glucagon-like peptide-1 receptor agonists ranked highest for all-cause mortality outcomes.
No publication bias was detected in the studies reviewed.

AI simplified

BACKGROUND: Type 2 diabetes (T2D) is associated with an increased risk of hepatocellular carcinoma (HCC). Research on the hepatoprotective effects of antidiabetic agents is ongoing. This study aimed to investigate the correlation between novel antidiabetic agents and HCC incidence in T2D patients through a network meta-analysis.

METHODS: The study followed a predefined PROSPERO-registered protocol (CRD420251068833) and reported results per the PRISMA extension for network meta-analysis. Databases such as PubMed, Web of Science, Cochrane Library, Embase, and Medline were searched from their inception to June 6, 2025. Eligible studies involved patients aged ≥ 18 with T2D, covering various antidiabetic drugs. Data extraction used standardized tables, with primary and secondary outcomes including HCC incidence, hepatic cirrhosis, hepatic metabolic dysfunction, and all-cause mortality.

RESULTS: A total of 5,018 citations were retrieved, with 28 cohort studies involving 18,212,739 participants meeting the inclusion criteria. No inconsistency was found among outcome studies. SGLT-2 inhibitors (SGLT-2i) were most effective in reducing HCC incidence. In secondary outcome analysis, SGLT-2i and Glucagon-like peptide-1 receptor agonist (GLP-1 RA) were most effective for reducing hepatic cirrhosis incidence. For hepatic metabolic dysfunction, SGLT-2i, GLP-1 RA, and DPP4i ranked from most to least effective. For all-cause mortality, GLP-1 RA ranked highest. No publication bias was detected.

CONCLUSION: This network meta-analysis indicates that SGLT-2i and GLP-1 RA may be preferred for T2D patients to reduce HCC incidence and other hepatic-related outcomes. Further research is needed to confirm these findings and explore the underlying mechanisms.

SYSTEMATIC REVIEW REGISTRATION: CRD420251068833.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

The correlation between novel antidiabetic agents utilization and hepatocellular carcinoma incidence in type 2 diabetes patients: a network meta-analysis

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief